Haima Therapeutics, LLC

Publicly observed

Cleveland, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Cleveland	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Haima Therapeutics, LLC	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	JKZPL4NA9V21	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding Management
USD 499,999.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Grant15 Jul 2025Publicly observed
NIH SBIR/STTR award: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents
USD 50,000.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Grant15 Jul 2025Publicly observed
NIH SBIR/STTR award: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents
USD 978,218.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Grant15 Jul 2025Publicly observed
NIH SBIR/STTR award: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents
USD 944,676.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Grant27 Mar 2025Publicly observed
NIH SBIR/STTR award: SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
USD 50,000.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.